17-Methyltestosterone Anabolic Androgenic Steroids CAS 58-18-4 Assay 99.5%

1. Quick Details:

2. Description :

Methyltestosterone (also known as Android, Androral, Oraviron, Testred, Virilon) is a 17-alpha-alkylated anabolic steroid and commonly it is used to treat men who do not make enough of a natural substance testosterone. It bears close structural similarity to testosterone, but has a methyl group at C17 in order to increase oral bioavailability.

In males, testosterone is responsible for many normal functions, including growth and development of the genitals, muscles, and bones. It also helps cause normal sexual development (puberty) in boys. Methyltestosterone is similar to the natural testosterone produced by your body. It belongs to a class of drugs known as androgens. It works by affecting many body systems so that the body can develop and function normally.

Methyltestosterone may also be used in certain adolescent boys to cause puberty in those with delayed puberty.

3. Indications and Usage for Methyltestosterone:

Males:

Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone:

Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy.

Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of Methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.

Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers.

Females:

Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field.

4. Dosage:

Male:

1) Usual Adult Dose for Hypogonadism
2) 10 to 50 mg orally once a day.

5 to 25 mg buccal tablet once a day. Buccal administration allows direct absorption of methyltestosterone into the systemic venous system resulting in delivery of unmetabolized drug to the target tissue. Potency of buccal tablets is 2 times that of oral methyltestosterone.

Female:

1) Usual Adult Dose for Breast Cancer-Palliative
2) 50 to 200 mg orally per day in divided doses.

25 to 100 mg buccal tablet per day. Buccal administration allows direct absorption of methyltestosterone into the systemic venous system resulting in delivery of unmetabolized drug to the target tissue. Potency of buccal tablets is 2 times that of oral methyltestosterone.

Methyltestosterone is approved by the FDA for the palliation of androgen-responsive metastatic breast cancer in women who are 1 to 5 years postmenopausal or who are proven to have a hormone-dependent tumor noted by previous beneficial response to castration.

Female patients :should be observed for signs of virilization. Women should be instructed to report any hoarseness, acne, changes in menstrual periods, or increase in facial hair. Discontinuation of drug therapy at the time of evidence of mild virilism is necessary to prevent irreversible virilization. A decision may be made by the patient and the physician that some virilization will be tolerated during the treatment for malignant disease.